BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38:322-327. [PMID: 12586298 DOI: 10.1016/s0168-8278(02)00419-1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Wu D, Zhang S, Xie Z, Chen E, Rao Q, Liu X, Huang K, Yang J, Xiao L, Ji F, Jiang Z, Zhao Y, Ouyang X, Zhu D, Dai X, Hou Z, Liu B, Deng B, Zhou N, Gao H, Sun Z, Li L. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. J Clin Invest 2020;130:2069-80. [PMID: 32175919 DOI: 10.1172/JCI130197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Oketani M, Uto H, Ido A, Tsubouchi H. Management of hepatitis B virus-related acute liver failure. Clin J Gastroenterol 2014;7:19-26. [PMID: 26183504 DOI: 10.1007/s12328-013-0447-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
3 Huang SC, Cheng PN, Liu CH, Yang HC, Su TH, Tseng TC, Chen PJ, Kao JH, Liu CJ. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. J Formos Med Assoc 2021:S0929-6646(21)00424-1. [PMID: 34538552 DOI: 10.1016/j.jfma.2021.09.002] [Reference Citation Analysis]
4 Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol 2011; 17(29): 3448-3452 [PMID: 21876637 DOI: 10.3748/wjg.v17.i29.3448] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
5 Chan HL. Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late? Dig Dis Sci 2010;55:2126-8. [PMID: 20458619 DOI: 10.1007/s10620-010-1266-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
6 Chen YC, Hsu CW, Chang MY, Yeh CT. On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. BMC Res Notes. 2013;6:349. [PMID: 24004574 DOI: 10.1186/1756-0500-6-349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Gao S, Joshi SS, Osiowy C, Chen Y, Coffin CS, Duan ZP. Chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants. Virol J. 2017;14:203. [PMID: 29065883 DOI: 10.1186/s12985-017-0870-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015; 7(8): 1097-1104 [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
9 Xie F, Yan L, Lu J, Zheng T, Shi C, Ying J, Shen R, Yang J. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One. 2013;8:e54773. [PMID: 23382964 DOI: 10.1371/journal.pone.0054773] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
10 Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 2013; 19(39): 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
11 Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol. 2012;47:1022-1029. [PMID: 22370817 DOI: 10.1007/s00535-012-0561-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
12 Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. PLoS One 2013;8:e65952. [PMID: 23776577 DOI: 10.1371/journal.pone.0065952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
13 Philips CA, Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol 2014; 20(43): 16037-16052 [PMID: 25473156 DOI: 10.3748/wjg.v20.i43.16037] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
14 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, Suzuki A, Suzuki H, Sadahiro T, Oda S. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43:711-719. [PMID: 18807133 DOI: 10.1007/s00535-008-2222-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
16 Tan W, Xia J, Dan Y, Li M, Lin S, Pan X, Wang H, Tang Y, Liu N, Tan S, Liu M, He W, Zhang W, Mao Q, Wang Y, Deng G. Genome-wide association study identifies HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure. Gut 2018;67:757-66. [PMID: 28130311 DOI: 10.1136/gutjnl-2016-313035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
17 Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55:2373-2380. [PMID: 20512414 DOI: 10.1007/s10620-010-1257-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
18 Seto WK, Yuen MF, Fung J, Lai CL. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int 2013;7:327-34. [PMID: 21688182 DOI: 10.1007/s12072-011-9282-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Lee KC, Cheng JS, Chang ML, Chien RN, Liaw YF. Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study. Hepatol Int 2022. [PMID: 35699864 DOI: 10.1007/s12072-022-10357-0] [Reference Citation Analysis]
20 Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Arai M, Fujiwara K, Goto N, Imazeki F, Yokosuka O. Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B. Int J Med Sci 2012;9:27-32. [PMID: 22211086 DOI: 10.7150/ijms.9.27] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
21 Yue-Meng W, Li YH, Wu HM, Yang J, Xu Y, Yang LH, Yang JH. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis. Clin Exp Med 2017;17:233-41. [PMID: 27094312 DOI: 10.1007/s10238-016-0420-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
22 Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2006;0:060606032707119. [DOI: 10.1111/j.1440-1746.2005.03534.x] [Reference Citation Analysis]
23 Zhang L, Hao CQ, Liu JF, Wang M. Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B. Virol J 2013;10:134. [PMID: 23627972 DOI: 10.1186/1743-422X-10-134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
24 Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774-80. [PMID: 21294143 DOI: 10.1002/hep.24109] [Cited by in Crossref: 180] [Cited by in F6Publishing: 158] [Article Influence: 16.4] [Reference Citation Analysis]
25 Fujiwara K, Yasui S, Okitsu K, Yonemitsu Y, Oda S, Yokosuka O. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2010;45:1255-1262. [PMID: 20614156 DOI: 10.1007/s00535-010-0280-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
26 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019; 25(19): 2327-2337 [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
27 Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan H, Chan FK, Sung JJ, Chan HL. Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. Antiviral Therapy 2008;13:571-9. [DOI: 10.1177/135965350801300407] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
28 Ichai P, Samuel D. Management of Fulminant Hepatitis B. Curr Infect Dis Rep 2019;21:25. [PMID: 31165271 DOI: 10.1007/s11908-019-0682-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol 2014; 20(23): 7306-7311 [PMID: 24966601 DOI: 10.3748/wjg.v20.i23.7306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
30 Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009;49:S129-37. [PMID: 19399799 DOI: 10.1002/hep.22931] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
31 Xu Y, Wu XN, Shi YW, Wei W, Yang AT, Sun YM, Zhao WS, You H. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis. Chin Med J (Engl) 2015;128:1867-72. [PMID: 26168824 DOI: 10.4103/0366-6999.160488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
33 Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM, Wang JH, Tsai MC, Kuo YH, Chang KC, Chiu YC, Chen CH. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. Antimicrob Agents Chemother 2015;59:3168-73. [PMID: 25779569 DOI: 10.1128/AAC.00261-15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
34 Lin SD, Ren Y, Liu LL. Identification and management of patients with severe exacerbation of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2017; 25(31): 2747-2753 [DOI: 10.11569/wcjd.v25.i31.2747] [Reference Citation Analysis]
35 Tsai WL, Sun WC, Cheng JS. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci. 2015;16:28126-28145. [PMID: 26703566 DOI: 10.3390/ijms161226087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
36 Chon YE, Choi EH, Song KJ, Park JY, Kim DY, Han KH, Chon CY, Ahn SH, Kim SU. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 2012;7:e44930. [PMID: 23049764 DOI: 10.1371/journal.pone.0044930] [Cited by in Crossref: 179] [Cited by in F6Publishing: 173] [Article Influence: 17.9] [Reference Citation Analysis]
37 Hung CH, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, Wang JH, Chang KC, Kuo YH, Yen YH, Hu TH, Lu SN. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. Clin Transl Gastroenterol 2017;8:e104. [PMID: 28662023 DOI: 10.1038/ctg.2017.29] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
38 Liu C, Ye J, Jia H, Zhang M, Han H, Chen F, Chen C. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp Ther Med. 2013;5:545-548. [PMID: 23403957 DOI: 10.3892/etm.2012.850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
39 Yuen MF. Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure. Hepatol Int 2015;9:373-7. [PMID: 25788180 DOI: 10.1007/s12072-014-9569-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
40 Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X, Wu B, Lin C, Gao Z. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatol Int. 2013;7:460-467. [PMID: 26201778 DOI: 10.1007/s12072-012-9415-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
41 Allali K, Meskaf A, Tridane A. Mathematical Modeling of the Adaptive Immune Responses in the Early Stage of the HBV Infection. International Journal of Differential Equations 2018;2018:1-13. [DOI: 10.1155/2018/6710575] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
42 Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010;55:775-783. [PMID: 19957031 DOI: 10.1007/s10620-009-1060-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
43 Liu JF, Zhang L, Feng GH. Advances in treatment of HBV-related liver failure with nucleoside analogues. Shijie Huaren Xiaohua Zazhi 2011; 19(9): 930-935 [DOI: 10.11569/wcjd.v19.i9.930] [Reference Citation Analysis]
44 Zhang Y, Hu XY, Zhong S, Yang F, Zhou TY, Chen G, Wang YY, Luo JX. Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol 2014; 20(16): 4745-4752 [PMID: 24782628 DOI: 10.3748/wjg.v20.i16.4745] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
45 Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462-469. [PMID: 26482576 DOI: 10.1007/s12072-015-9667-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
46 Zhong Y, Guo Y, Liu X, Zhang J, Ma T, Shu J, Yang J, Zhang J, Jia Z, Li Z. Serum Glycopatterns as Novel Potential Biomarkers for Diagnosis of Acute-on-Chronic Hepatitis B Liver Failure. Sci Rep 2017;7:45957. [PMID: 28383031 DOI: 10.1038/srep45957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
47 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
48 Tsai WL, Chiang PH, Chan HH, Lin HS, Lai KH, Cheng JS, Chen WC, Tsay FW, Wang HM, Tsai TJ, Yu HC, Hsu PI. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother 2014;58:1918-21. [PMID: 24419351 DOI: 10.1128/AAC.02400-13] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
49 Peng CY, Chen CB, Lai HC, Su WP, Chuang PH, Wu HD, Jeng LB. Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. Hepatol Int 2010;5:586-96. [PMID: 21442057 DOI: 10.1007/s12072-010-9227-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
50 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 661] [Article Influence: 45.4] [Reference Citation Analysis]
51 Yang J, Sun H, Liu Q. The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2016;2016:5802674. [PMID: 27148364 DOI: 10.1155/2016/5802674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]